GlassScriptPhysician profile
Robert Fleyshman
NPI 1194130898
$2,103.28
in general payments reported to CMS, 2019-2025
16 companies · $469 in 2025
The $469 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $390 · 2020: $27.78 · 2021: $177 · 2022: $535 · 2023: $114 · 2024: $391 · 2025: $469.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $953 · Education: $20.22.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $953.48 |
| Education | $20.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $418.26 | 2019-2025 | Veltassa |
| Bayer Healthcare Pharmaceuticals INC. | $400.05 | 2021-2024 | |
| Astrazeneca Pharmaceuticals LP | $250.02 | 2022-2024 | Farxiga, Lokelma |
| Ardelyx, INC. | $219.06 | 2024-2025 | Xphozah 30 Mg, Ibsrela |
| Otsuka America Pharmaceutical, INC. | $152.15 | 2024-2025 | Jynarque |
| Abbott Laboratories | $130.17 | 2019 | |
| Mallinckrodt Hospital Products INC. | $121.38 | 2025 | Terlivaz |
| Genzyme Corporation | $99.13 | 2019 | |
| Amgen INC. | $84.31 | 2022-2025 | Tavneos, Krystexxa |
| Novartis Pharmaceuticals Corporation | $48.36 | 2024-2025 | |
| Opko Pharmaceuticals, LLC | $48.19 | 2021-2022 | |
| Calliditas Therapeutics US INC. | $35.90 | 2025 | Tarpeyo |
| Novo Nordisk INC | $35.70 | 2025 | Ozempic |
| Akebia Therapeutics INC | $28.02 | 2020-2021 | |
| Scpharmaceuticals INC. | $17.66 | 2025 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $14.92 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Fleyshman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.